27 June 2024
Eden
Research
("Eden"
or "the Company")
Result of Annual General
Meeting
Eden Research plc (AIM: EDEN), the
AIM-quoted company focused on sustainable biopesticides and
plastic-free formulation technologies for use in the global crop
protection, animal health and consumer products industries, is
pleased to announce that all resolutions put forward to
shareholders at the Company's Annual General Meeting held earlier
today were duly passed.
The total number of votes received
by proxy on each resolution, as more fully disclosed in the Notice
of Meeting available on the Company's website, was as
follows:
|
#
|
Resolution
|
For
|
%
|
Against
|
%
|
Withheld
|
|
1
|
To lay the 2023 Annual
Report
|
230,082,724
|
93.89
|
14,978,000
|
6.11
|
14,818,795
|
|
2
|
Re-appoint auditors
|
259,337,444
|
99.87
|
332,075
|
0.13
|
210,000
|
|
3
|
Elect Derek McAllan
|
259,473,982
|
99.99
|
11,691
|
0.01
|
393,846
|
|
4
|
Re-elect Sean Smith
|
259,469,698
|
99.94
|
154,821
|
0.06
|
255,000
|
|
5
|
Grant authority to the Directors to
allot Ordinary Shares
|
252,687,622
|
97.32
|
6,962,053
|
2.68
|
229,844
|
|
6
|
Disapply statutory pre-emption rights
on allotment of shares*
|
259,377,414
|
99.93
|
193,415
|
0.07
|
308,690
|
Notes:
·
* denotes Special Resolution.
·
A vote Withheld is not a vote in law and is not
counted in the calculation of the votes cast For or Against the
resolution, nor in the calculation of the percentage of issued
share capital voted for any resolution.
·
Votes For and Against are expressed as a
percentage of votes validly cast for that resolution by proxy,
excluding any Withheld votes.
For further information
contact:
|
Eden Research plc
|
|
|
Sean Smith
Alex Abrey
|
www.edenresearch.com
01285 359
555
|
|
Cavendish Capital Markets Limited (Nominated advisor and
broker)
|
|
|
Giles Balleny / George
Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)
|
020 7220
0500
|
|
Hawthorn Advisors (Financial PR)
|
|
|
Victoria Ainsworth
|
eden@hawthornadvisors.com
|
Notes to Editors:
Eden Research is the
only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative
biopesticide products and natural microencapsulation technologies
to the global crop protection, animal health and consumer products
industries.
Eden's products are formulated with
terpene active ingredients, based on natural plant defence
metabolites. To date, they have been primarily used on high-value
fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional
pesticides. Eden has three products currently on the
market:
Based on plant-derived active
ingredients, Mevalone® is a foliar biofungicide which
initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops. It is a useful
tool in crop defence programmes and is aligned with the
requirements of integrated pest management programmes. It is
approved for sale in a number of key countries whilst Eden and its
partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.
Cedroz™ is a
bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and
vegetable crops globally. Cedroz is registered for sale on
two continents and Eden's commercial collaborator, Eastman
Chemical, is pursuing registration and commercialisation of this
important new product in numerous countries globally.
Eden's seed treatment
product, Ecovelex was developed to safely
tackle crop destruction caused by birds - a major cause of losses
in maize and other crops. Ecovelex works by creating an
unpleasant taste or odour that repels birds, leaving the seeds
safely intact and the birds unaffected and free to find alternative
food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated
using Eden's Sustaine® microencapsulation system.
Eden's Sustaine® encapsulation
technology is used to harness the biocidal efficacy of naturally
occurring chemicals produced by plants (terpenes) and can also be
used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres
derived from yeast. It is one of the only viable, proven and
immediately registerable solutions to the microplastics problem in
formulations requiring encapsulation.
Eden was admitted to trading on AIM
on 11 May 2012 and trades under the symbol EDEN. It was
awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services
that contribute to the global green economy. Eden derives 100% of
its total annual revenues from sustainable products and
services.
For more information about Eden,
please visit: www.edenresearch.com.